Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.91
+0.11006.11%
Post-market: 1.920.0100+0.52%19:44 EDT
Volume:2.45M
Turnover:4.71M
Market Cap:159.89M
PE:-0.63
High:1.97
Open:1.81
Low:1.80
Close:1.80
Loading ...

Editas Medicine Inc. EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares

Reuters
·
05 Jun

Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares

Reuters
·
05 Jun

Editas Medicine Inc. Conducted Annual Stockholders Meeting

Reuters
·
03 Jun

Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Transform Therapeutics Globally

Reuters
·
29 May

Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations

TIPRANKS
·
17 May

Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine

TIPRANKS
·
16 May

BRIEF-Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas’ Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting

Reuters
·
14 May

Editas Medicine Announces Promising Preclinical Results for In Vivo Gene Editing Approach to Treat Sickle Cell Disease and Beta Thalassemia

Reuters
·
14 May

Editas Medicine Reports New in Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in Hscs at the American Society of Gene and Cell Therapy Annual Meeting

THOMSON REUTERS
·
14 May

Editas Medicine Is Maintained at Outperform by Baird

Dow Jones
·
13 May

Editas Medicine Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

Benzinga
·
13 May

Editas Medicine Inc. to Showcase Preclinical Gene Editing Advances at ASGCT Annual Meeting

Reuters
·
13 May

BRIEF-Editas Medicine Q1 Net Income USD -76.088 Million

Reuters
·
13 May

Editas Medicine Inc - Cash Runway Into Q2 2027

THOMSON REUTERS
·
13 May

Editas Medicine Announces First Quarter 2025 Results and Business Updates

THOMSON REUTERS
·
13 May

Editas Medicine Q1 Operating Income USD -76.163 Million

THOMSON REUTERS
·
13 May

Editas Medicine : Co's in-Licensed Patents Covering CRISPR/Cas12a Are Not at Issue in Interference and Are Unaffected by This Decision

THOMSON REUTERS
·
13 May

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

THOMSON REUTERS
·
13 May

North American Morning Briefing: Stock Futures Surge on China Deal

Dow Jones
·
12 May